# A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

> **NCT05076149** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 597 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-121/TEZ/D-IVA
- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA
- **DRUG:** Placebo (matched to VX-121/TEZ/D-IVA)
- **DRUG:** Placebo (matched to ELX/TEZ/IVA)
- **DRUG:** Placebo (matched to IVA)

## Key facts

- **NCT ID:** NCT05076149
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-27
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-11-30
- **Target enrollment:** 597 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05076149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05076149, "A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05076149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*